Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1)

  • STATUS
    Recruiting
  • End date
    Jun 18, 2025
  • participants needed
    195
  • sponsor
    AstraZeneca
Updated on 4 October 2022

Summary

This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in patients with advanced cancer that has recurred/progressed.

Description

This is a modular phase I/IIa, multi-centre, multi-part, open-label, dose escalation, and dose expansion study.

Approximately 255 participants will be enrolled and assigned to study treatments.

This study consists of individual modules each evaluating safety and tolerability.

  • Core protocol which contains information applicable to all modules.
  • Module 1 (AZD9574 monotherapy):
  • Part A (dose-escalation cohorts) will include participants with advanced/relapsed ovarian, breast, pancreatic or prostate cancer that are deemed suitable for a Poly ADP-Ribose Polymerase (PARPi) by the Investigator.
  • Part B (dose-expansion cohorts):
  • Cohort B1 will include participants with advanced/relapsed Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer participants with BRCA mutated (BRCA1m, and BRCA2m), PALB2 mutation (PALB2m), RAD51Cm or RAD51Dm, without evidence of brain metastasis at baseline Magnetic Resonance Imaging (MRI) scan.
  • Cohort B2 will include participants with advanced/relapsed HER2-negative breast cancer participants with BRCA1m, BRCA2m, PALB2m, RAD51Cm or RAD51Dm, who have either untreated or treated brain metastases that are not requiring immediate local therapy.
  • Module 2 (AZD9574 in combination with temozolomide (TMZ):
  • Part A (dose-escalation cohorts) will include participants with Isocitrate Dehydrogenase (IDH)-mutant glioma.
  • Dose expansion for Module 2 may be added in the future following a protocol amendment.

Details
Condition Advanced Solid Malignancies
Treatment Temozolomide, AZD9574
Clinical Study IdentifierNCT05417594
SponsorAstraZeneca
Last Modified on4 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Eastern Cooperative Oncology Group performance status (ECOG PS) with no deterioration over the previous 2 weeks
Progressive cancer at the time of study entry
Non-sterilised male participants who are sexually active with a female partner of childbearing potential must use a condom with spermicide from screening to approximately 3 months after the last dose of study intervention
Adequate organ and marrow function
Module 1
Female participants of childbearing potential must have a negative pregnancy test result at screening and prior to each cycle administration of AZD9574
Part A
Participants must have one of the following
(i) Histologically or cytologically confirmed relapsed advanced ovarian
fallopian tube or primary peritoneal cancer and evidence of a predicted loss
of function germline or tumour mutation in one of the following homologous
recombination repair genes: BRCA1, BRCA2, PALB2, RAD51C or RAD51D (ii)
Histologically or cytologically confirmed HER2-negative carcinoma of the
breast with recurrent locally advanced or metastatic disease and evidence of a
predicted loss of function germline or tumour mutation in one of the following
homologous recombination repair genes: BRCA1, BRCA2, PALB2, RAD51C, or RAD51D
(iii) Histologically or cytologically confirmed advanced/metastatic
castration-resistant prostate cancer (CRPC) and evidence of a predicted loss
of function germline or tumour mutation in one of the following homologous
recombination repair genes: BRCA1, BRCA2, PALB2, RAD51C, or RAD51D (d)
Histologically or cytologically confirmed advanced/metastatic pancreatic
cancer and evidence of a predicted loss of function germline or tumour
mutation in one of the following homologous recombination repair genes: BRCA1
BRCA2, PALB2, RAD51C, or RAD51D
Participants must have evaluable disease
Patients must be suitable for treatment with a PARPi
Part B
Participants must have metastatic or recurrent locally advanced histologically or cytologically confirmed Human Epidermal growth factor Receptor 2 (HER2)-negative carcinoma of the breast and evidence of a predicted loss of function germline or tumour mutation
Participants must have at least one lesion, not previously irradiated, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter
Participants who have received platinum chemotherapy for advanced breast cancer are eligible to enter the study provided there has been no evidence of disease progression during the platinum chemotherapy
Participants who have received prior platinum-based chemotherapy as neo-adjuvant/adjuvant treatment are eligible provided at least 12 months have elapsed between the last dose of platinum-based treatment and first dose of study intervention
Module 2
Participants must be suitable for treatment with TMZ
Participants must have IDH1/2-mutant glioma
Participants should have progressive disease after prior radiation therapy and one prior line of alkylating chemotherapy for their disease
Recurrent disease must be evaluable by MRI
Female participants of childbearing potential must have a negative pregnancy test result at screening and prior to each cycle administration of AZD9574 and TMZ
Adequate organ and marrow function

Exclusion Criteria

Major surgery within 4 weeks of the first dose of study intervention
Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 2 weeks of the first dose of study intervention
With the exception of alopecia, any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 at the time of starting study intervention
Any known history of persisting severe pancytopenia due to any cause
Spinal cord compression unless asymptomatic, treated and stable and not requiring continuous corticosteroids at a dose of > 10 mg prednisone/day or equivalent for at least 4 weeks prior to start of study intervention
History of uncontrolled seizures or with need for concurrent administration of more than 2 antiepileptic drugs, or history of epileptic disorder or any seizure history unrelated to tumour
History of severe brain injury or stroke
Any evidence of severe or uncontrolled systemic diseases including active bleeding diatheses, active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV)
Uncontrolled intercurrent illness within the last 12 months
Any known predisposition to bleeding
Patients with myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML) or with features suggestive of MDS/AML
Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD9574
Known allergy or hypersensitivity to investigational product(s) or any of the excipients of the investigational product(s)
Known contra-indication to gadolinium-enhanced Magnetic Resonance Imaging (MRI) or, if applicable, not able to be maintained on a stable or decreasing dose of corticosteroid regimen (no increase for 7 days) prior to the baseline MRI
Any concurrent anti-cancer therapy or concurrent use of prohibited medications
Module 1
Part A
Participants that have received > one prior line of therapy in any setting with a PARPi-based regimen
Participants with an INR >1.5 unless the patient is receiving non-vitamin K antagonist oral anticoagulants
Participants with LMD unless the LMD is of low volume or is previously irradiated and the participant is asymptomatic from the LMD
Part B
Participants with an International Normalised Ratio (INR) >1.5 unless the patient is receiving non-vitamin K antagonist oral anticoagulants
Participants with LMD are excluded unless the LMD is of low volume or is previously irradiated and the participant is asymptomatic from the LMD
Module 2
Participants who have received a PARPi previously
Known hypersensitivity to TMZ or dacarbazine or known history of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD9574
Participants who have received > 1 prior line of alkylating chemotherapy regimen
Participants who had previously experienced Grade 4 haematological toxicities or Grade 3 neutropenia associated with infections, or Grade 3 thrombocytopenia with clinically significant bleeding during prior alkylating chemotherapy
Participants who have received bevacizumab within the last 6 months
Not requiring continuous corticosteroids at a dose of >10 mg prednisone/day or equivalent for at least 4 weeks prior to start of study intervention
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note